美股异动 | 生物医药公司Evommune(EVMN.US)登陆美股市场 股价涨超15%

Core Viewpoint - Evommune (EVMN.US) has successfully launched on the US stock market, with its stock price increasing over 15% to $18.38, compared to its IPO price of $16 [1] Company Overview - Evommune is a clinical-stage biopharmaceutical company focused on developing innovative therapies for the treatment of immune-mediated chronic inflammatory diseases [1] - The diseases targeted by Evommune include chronic urticaria, atopic dermatitis, and other conditions related to mast cells and inflammation [1]